News

Johns Hopkins All Children’s Hospital’s Hypertrophic Cardiomyopathy Program Named a Center of Excellence June 19, 2026 ST. PETERSBURG, FL, UNITED STATES, June 19, 2026…

MaineHealth Program Earns National Recognition for Specialized Hypertrophic Cardiomyopathy Care June 18, 2026 MaineHealth is the only HCMA-recognized Center of Excellence in Northern New…

North Shore University Hospital designated a Recognized Center of Excellence for Hypertrophic Cardiomyopathy May 21, 2026 Prestigious recognition reflects commitment to specialized care for…

Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026…

The Hypertrophic Cardiomyopathy Association (HCMA) Welcomes Our Newest Recognized Center of Excellence – Indiana University Health Methodist February 27, 2026 1.3 million Americans, likely…

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) SCOUT-HCM…

Tampa General Hospital Earns HCMA Center of Excellence Designation for Hypertrophic Cardiomyopathy Care December 12, 2025 Tampa General Hospital (TGH) has been recognized as…

Sixty years ago, Medicaid and Medicare were created when President Lyndon B. Johnson signed the Social Security Amendments into law. These programs were central…

HCMA Welcomes Three New Board Members July 9, 2025 Jan Berger, MD, MJ is an independent director with significant board and committee experience, a…

What is a Center of Excellence (COE)? A Center of Excellence is a team of specialists who provide high-quality care to patients with a…

EC has granted approval for the treatment of ATTR-CM as an additional indication for AMVUTTRA® (vutrisiran) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA…